Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Genesis Health

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

Genesis Health
Site position #331

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 61.4/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +40
92
52
Dose & formulationCoreAge Rx +11
88
77
Clinical oversightCoreAge Rx +38
93
55
Labs & monitoringCoreAge Rx +27
90
63
FulfillmentCoreAge Rx +22
95
73
Contract termsCoreAge Rx +20
67
47
CoreAge Rx · top barGenesis Health · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxGenesis Health
WeighScore89.5/10061.4/100
GradeB+C
Site position#1#331
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$175/mo (starting dose, compounded)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$235/mo (starting dose, compounded)
CoverageUS only; therapy-specific state restrictions applyCoverage not published
Brand-name accessNot confirmedYes
Oral / sublingualNot confirmedNot confirmed
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Genesis Health

Site position #331 · C

FDAWarning letter issued to Genesis Health International Inc. dba Genesis in February 2026. See the FDA warning-letter database.

Strengths

  • Annual plan as low as $99/mo for semaglutide or $125/mo for tirzepatide
  • Offers both compounded and brand-name GLP-1s (Wegovy, Ozempic, Zepbound) in one platform
  • Includes health coaching, active community, and free expedited shipping on every plan
  • LegitScript certified; medications sourced from audited, licensed US compounding pharmacies
  • Same-day provider visits, personalized dosing, and 24/7 care team messaging

What to consider

  • States served not publicly listed; telehealth coverage unconfirmed for all states
  • Monthly starting price ($175 sema / $235 tirz) is mid-market without annual commitment
  • Labs not disclosed or included in any published plan tier
  • Brand-name GLP-1 pricing not published; insurance or coupon required
  • FDA issued Genesis Health International Inc. dba Genesis a warning letter in February 2026; the letter is public in FDA's warning-letter database

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard